Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Immutep S.A.

ArriVent Is Second Positive IPO Of 2024 After CG Oncology’s Debut

ArriVent launched the second biopharma initial public offering of 2024, closing above its IPO price on its first day and grossing $175m – and keeping the financial market mood optimistic.

Financing Cancer

Finance Watch: The Rush To End 2023 With Fresh VC Cash For Biopharma

Private Company Edition: Playground’s third fund has $410m for tech, including biotech, Pivotal Life Sciences closed its second fund with $389m and Chugai will invest $200m through its new fund. Also, Tome launched with $213m, Sudo raised a $116m series B and Odyssey closed a $101m in series C.

Financing Innovation

Intercept Ends NASH Development, But Other Firms’ FXR Agonist Programs Ongoing

While Intercept is calling it quits in NASH with its FXR agonist obeticholic acid following a second complete response letter, other companies are staying the course with Phase II molecules in the class.

Drug Approval Standards Complete Response Letters

Finance Watch: Mega-Rounds Make A Comeback, But Will VC Funding Totals Rise Too?

Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.

Finance Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register